by 
Cell-based assays are widely used tools in drug discovery, disease pathogenesis, and basic cell biology research. They are especially useful in pharmaceutical and biotechnology industries, for applications ranging from basic research to safety assessments and drug efficacy testing. Cell lines from different tissue types are utilized to study specific cell responses under various conditions. Cell-based assays allow high-throughput screening of large chemical libraries to identify hits for further development. The global cell-based assay market is estimated to be valued at US$ 1389.05 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Growing Pharmaceutical and Biotechnology Industries (as referred in the heading) is one of the primary drivers fueling growth of the global cell-based assay market. The pharmaceutical industry is undergoing rapid transformation led by advancements in genomics, biologics, and personalized medicine. Cell-based assays are crucial for preclinical drug testing, target identification and validation, and assessing drug toxicity and efficacy. Further, increasing demand for efficient drug discovery tools and the need to reduce unwanted side effects of drugs are also propelling adoption of cell-based assays. Additionally, rising investments by both public and private sectors into life sciences research will continue pushing market expansion during the forecast period.
Segment Analysis
The cell-based assay market is dominated by the consumables segment which holds around 60% market share. This is because consumables such as plates, reagents, buffers are required in high quantity for each assay performed. Within the consumables, reagents segment holds the largest share as different types of reagents are needed for specific cell-based assays. The instruments segment follows consumables with around 25% share due to high cost of instruments compared to consumables. Services segment has around 15% share which include services such as consulting, data analysis and cell lines authentication.
PEST Analysis
Political: The market is positively impacted by government funding for cell-based research and drug development. However, strict regulations for product approval delays commercialization.
Economic: Growth of the economy and increasing healthcare spending boosts the market. High set up costs of laboratories limits growth in developing nations.
Social: Rising awareness about personalized medicine and cell therapy increases demand for cell-based assays for research.
Technological: Advancements in high throughput screening, miniaturization, and automation has increased assay speed and throughput. Introduction of microfluidics and lab-on-chip technologies is further enhancing capabilities.
Key Takeaways
The global cell-based assay market is expected to witness high growth over the forecast period supported by factors such as increasing pharmaceutical R&D expenditure, stem cell research funding, and adoption of cell-based validation in drug discovery.
Regional analysis: North America dominated the market with around 40% share due to presence of major players and availability of advanced research infrastructure. Asia Pacific is expected to grow at the fastest pace owing to emerging economies investing in healthcare research.
Key players: Key players operating in the cell-based assay market are DiscoverX Corporation, Becton, Dickinson and Company, cell Signaling Technology, Inc., Becton, Danaher Corporation, Thermo Fisher Scientific, Inc., Cisbio Bioassays, Merck & Co., and PerkinElmer, Inc. DiscoverX Corporation offers largest assay platforms for ion channel and GPCR targets. Becton, Dickinson and Company provides microplates, reagents and analyzers used in cell-based assays.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
